SPX3,775.07-15.86 -0.42%
DIA302.36-0.78 -0.26%
IXIC11,097.10-79.31 -0.71%

BRIEF-Sermonix Announces Results Of Phase 2 Study Of Lasofoxifene Versus Fulvestrant

BRIEF-Sermonix Announces Results Of Phase 2 Study Of Lasofoxifene Versus Fulvestrant

Reuters · 09/13/2022 09:34
BRIEF-Sermonix Announces Results Of Phase 2 Study Of Lasofoxifene Versus Fulvestrant

- Ligand Pharmaceuticals Inc LGND.O:

  • SERMONIX ANNOUNCES RESULTS OF PHASE 2 STUDY OF LASOFOXIFENE VERSUS. FULVESTRANT IN POSTMENOPAUSAL WOMEN WITH LOCALLY ADVANCED OR METASTATIC ER+/HER2- BREAST CANCER AND AN ESR1 MUTATION

Source text for Eikon: ID:

Further company coverage: LGND.O


((reuters.briefs@thomsonreuters.com;))